Chemical Namenirmatrelvir and ritonavir
Dosage FormTablet (oral; 150 mg nirmatrelvir co-packaged with 100 mg ritonavir)
Drug ClassMultiple
Approval Year2021


  • For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Please note that the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved Paxlovid.
Document TitleYearSource
Paxlovid (nirmatrlvir and ritonavir) Prescribing Information.2022Pfizer Inc., New York, NY
Drug updated on 5/31/2023

More on this drug: Clinical Trials